ENहिन्दी soon
Home/India/Blog/Weight-loss injections in India
INIndia Medicines

Which weight-loss injections are approved in India?

The weight-loss injections and medicines in India, brand by brand, set against diabetes-only brands and clinic "fat-loss" shots.

GLP Guidebook teamPublished 5 Oct 202613 min read42 sourcesWritten from published sources

Written for India. Reading from the US? US versionComing soon

The short answer

Semaglutide 2.4 mg (Wegovy, Poviztra, some generics) and tirzepatide (Mounjaro, Yurpeak) are weekly GLP-1 injections sold here for weight. A CDSCO panel also backed one liraglutide pen for weight in 2025. Orlistat is an older capsule. Ozempic and Trulicity are diabetes medicines. Clinic "fat-loss" shots are not approved weight treatments.

Before you go further
  • Every medicine below is prescription-only. They can't be bought over the counter.26
  • A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.39
  • Risks are real: see Guide 5: Side effects and risks.
  • Some batches of three generic semaglutide brands were recalled in July 2026.38 Check your pack against the list in Guide 6.
  • No promise of results. Approval means a medicine is allowed for a use, not that it will work for you.
  • We list brands as facts. We don't recommend any brand, company or seller.

Key takeaways

  • Semaglutide 2.4 mg and tirzepatide are the weekly GLP‑1 injections sold in India for weight, as Wegovy, Poviztra, Mounjaro, Yurpeak and some generics.3, 7, 10, 12, 14
  • A CDSCO expert panel recommended Eris Lifesciences' liraglutide pen for weight management on 6 February 2025; we found no report of its final approval or launch.35
  • Generic semaglutides from Sun Pharma, Alkem and Zydus were cleared for weight management after Phase 3 trials, which Sun Pharma and Alkem say were run in India.13, 14, 15
  • Ozempic is approved in India for type 2 diabetes only, so a prescription for weight alone is "off-label".17, 18
  • The US regulator has approved only one fat-dissolving injection, Kybella, and only for fat under the chin, not for weight loss.28, 29
On this page
  1. Which injections are approved for weight?
  2. Why isn't Ozempic on the weight list?
  3. Who can prescribe them, and who are they for?
  4. What are clinic "fat-loss injections"?
  5. Do fat-dissolving injections work?
  6. Do MIC, B12 or HCG shots help?
  7. Is there an approved weight-loss tablet?
  8. Questions people ask
  9. How we researched this
  10. Sources

Which injections are approved for weight management in India?

Semaglutide 2.4 mg and tirzepatide are the weekly GLP‑1 injections sold in India for weight management, under several brand names.3, 10, 12, 14 A CDSCO panel has also backed one liraglutide pen for weight.35

India's drug regulator is the Central Drugs Standard Control Organisation (CDSCO). Its expert panel recommended semaglutide's pens up to 2.4 mg in August 2021, in line with the US-approved use.2 CDSCO records show semaglutide pens in those strengths approved on 20 April 2022, "for various indication".1 That record names no brand and doesn't list the uses. Wegovy went on sale in June 2025.3

Tirzepatide was approved here for type 2 diabetes on 19 January 2024.8 In June 2024 the expert panel recommended it for "chronic weight management" too.9 Lilly launched it as Mounjaro on 20 March 2025, after CDSCO's marketing authorisation.10 We could not find the date of a formal weight approval, so the table shows the panel date.

Sources disagree on Mounjaro. Lilly calls it a treatment for obesity, overweight and type 2 diabetes.10 Cipla, which sells it as Yurpeak, says Lilly received DCGI approval and lists chronic weight management among its uses.12 But a 2026 review from AIIMS Bhopal says Mounjaro is approved for diabetes and used for obesity as well.24 We can't settle this from published records.

Liraglutide is a third case. On 6 February 2025, CDSCO's panel recommended Eris Lifesciences' liraglutide 6 mg/ml pen "for the treatment of weight management".35 It asked for a Phase IV trial after approval.35 We found no report of a final approval or a launch for weight.

The table separates weight uses from diabetes-only launches. Within each group, brands are listed A to Z, not ranked.

BrandMedicineCompanyApproved or launchedForm
Approved or recommended for weight management
Eris's liraglutideLiraglutide (generic, synthetic)Eris LifesciencesPanel recommended for weight 6 Feb 2025; final approval and launch not found35Pre-filled pen, 6 mg/ml35
MounjaroTirzepatideEli LillyDiabetes approval 19 Jan 2024; weight use recommended by the panel June 2024; on sale 20 Mar 20258, 9, 10Weekly vial; KwikPen (multi-dose pen) from Aug 202511
NoveltreatSemaglutide (generic)Sun PharmaApproval announced 23 Jan 2026; on sale 21 Mar 202614, 16Weekly pen14
Obesema, Semasize, HepaglideSemaglutide (generic)AlkemPanel recommended for weight 9 Dec 2025; DCGI approval for weight and diabetes announced, on sale 21 Mar 202613, 15Weekly pen, disposable or reusable15
PoviztraSemaglutide 2.4 mgNovo Nordisk; sold by EmcureSecond brand of Wegovy, announced 10 Nov 20257Weekly pen7
Semaglyn, Mashema, Alterme (Lupin sells it as Semanext, Livarise)Semaglutide (generic)ZydusPanel recommended for weight and diabetes 9 Dec 2025; on sale 21 Mar 202613, 16Weekly reusable pen16
WegovySemaglutide, up to 2.4 mgNovo NordiskSemaglutide pens in these strengths approved 20 Apr 2022 (record names no brand or use); on sale June 2025. Teens 12+ over 60 kg, and a fatty-liver use (MASH), added in 20261, 3, 5, 6Weekly pen3
YurpeakTirzepatideEli Lilly; sold by CiplaLaunched 10 Dec 2025, for weight and diabetes12Weekly KwikPen12
Launched for type 2 diabetes; no weight approval found (5 Oct 2026)
Biocon's liraglutideLiraglutide (generic)BioconApproval announced 2 Jun 202521Daily pen or cartridge21
GLIPIQSemaglutide (generic)GlenmarkOn sale 21 Mar 202616Weekly vial or pen16
LirafitLiraglutide (generic)GlenmarkLaunched Jan 202420Daily pen20
ObedaSemaglutide (generic)Dr Reddy'sOn sale 21 Mar 202616Weekly pen16
OzempicSemaglutide, up to 1 mgNovo NordiskLaunched for diabetes 12 Dec 202518Weekly pen18
RybelsusSemaglutideNovo NordiskTablets approved 27 Jul 20201, 19Daily tablet, not an injection1
SematrinitySemaglutide (generic)Sun PharmaOn sale 21 Mar 202616Weekly multi-dose pen16
TrulicityDulaglutideEli LillyLaunched Mar 201623Weekly pen23
VictozaLiraglutideNovo NordiskDCGI approval Jan 2010; launched 7 Jun 201036Daily pen20

Dates come from CDSCO panel minutes, CDSCO's 2024 new-drug list, press releases and named news reports, checked 5 Oct 2026. Where we found no formal approval date, we give the panel recommendation or the launch date and say which. Not a full list: at least 17 generic semaglutide versions were on sale by 31 March 2026.17 For MRPs, see Guide 6.

Why isn't Ozempic on the weight list?

Ozempic and Wegovy contain the same medicine, semaglutide, but Ozempic is indicated for diabetes, while Wegovy is prescribed for obesity and weight management.17

Ozempic launched here in December 2025 as a diabetes treatment, in 0.25, 0.5 and 1 mg strengths.18 Wegovy's doses go up to 2.4 mg.3 Using a medicine outside its approved use is called "off-label". Business Standard reports that Ozempic is widely prescribed off-label for weight loss.18 That is a doctor's decision, and it is not the same as an approval.

Generics are approved brand by brand. Dr Reddy's Obeda and Glenmark's GLIPIQ were launched for diabetes, while Sun Pharma's Noveltreat was launched for weight.16 Alkem and Zydus hold both uses.15, 16 Sun Pharma, Alkem and Zydus won their weight approvals after CDSCO's expert panel accepted their Phase 3 trial reports.13 Sun Pharma and Alkem say those trials were run in India.14, 15 So the word "semaglutide" on a pack doesn't tell you what that brand is approved for.

Tablets are different again. Rybelsus, the semaglutide tablet, is approved in India for type 2 diabetes.19 A 2026 review from AIIMS Bhopal says oral semaglutide is not formally approved for obesity here.24 Our Ozempic tablets post covers it.

Who can prescribe these injections, and who are they meant for?

Every injection in the table is prescription-only. A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.39

CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.40, 41

When CDSCO's panel first recommended semaglutide's weight pens in 2021, it set 2 conditions. Only endocrinologists should prescribe it, and treatment should run up to 68 weeks, the length of the trials.2 For teenagers, the 2026 recommendation names endocrinologists or paediatricians.4

The approvals use international weight cut-offs. The generic weight approvals cover adults with a body mass index (BMI) of 30 or more.13 They also cover a BMI of 27 or more with a weight-related condition, such as high blood pressure.13

Those are drug cut-offs, not India's definition of obesity. A 2009 Indian consensus counts a BMI of 23 to 24.9 as overweight and 25 or more as obesity.42 India's obesity guideline (ESI 2025) uses lower numbers for Indians. It says a doctor may consider medicines at a BMI above 27, or above 25 with a related condition.25

A BMI number starts a conversation with a doctor. It isn't a pass. ESI also says these medicines don't replace changes to food and activity.25 Guide 4 covers who should, and shouldn't, consider them.

RisksThe risks, in brief
  • Stomach effects are common: feeling sick, vomiting, diarrhoea, constipation and bloating.25
  • Pancreatitis (a swollen pancreas) is a listed warning.25
  • Gallbladder problems: gallstones and an inflamed gallbladder.25
  • Kidneys: sudden (acute) kidney injury is a listed warning.25
  • Thyroid warning: ruled out by India's ESI 2025 obesity guideline for anyone with a personal or family history of medullary thyroid cancer or MEN 2; tell your doctor if this applies. Not in pregnancy or breastfeeding.25
Full detail in Guide 5: Side effects and risks →
Get help now: call 112. Severe stomach pain that won't go away, sometimes spreading to your back, can be a sign of pancreatitis. It may come with or without vomiting.33
Free toolCould a GLP‑1 medicine be an option to discuss?

A short self-check using Indian guideline numbers. It doesn't decide anything; it helps you prepare. No sign-up.

Open the self-check

What are the "fat-loss injections" that clinics sell?

Outside the approved medicines, the name "fat-loss injection" covers at least three kinds of shot: fat-dissolving shots, vitamin "MIC" shots and HCG hormone shots.28, 32, 34

  • Fat-dissolving (lipolysis) shots. Chemicals are injected into a pocket of fat to break down fat cells. Common ingredients are phosphatidylcholine and sodium deoxycholate.28
  • MIC or "lipotropic" shots. These usually mix methionine, inositol and choline, often with vitamin B12.34
  • HCG shots. HCG is a hormone. In the US, approved HCG is prescription-only, for fertility and some hormone problems, not weight.32

None of these is a GLP‑1 medicine, and none appears in the table above. The drug regulator has warned that promoting GLP‑1 obesity medicines with guaranteed weight-loss results may count as misleading.27 By 1 April 2026, officials had inspected 49 businesses over the sale and promotion of GLP‑1 medicines, including weight-loss clinics.26

Do fat-dissolving injections work, and are they safe?

Only one fat-dissolving drug, deoxycholic acid (Kybella), is approved in the US, and only to treat fat under the chin.28, 29 It isn't approved as a weight-loss treatment.29

Kybella's US label says its use outside the chin area "has not been established and is not recommended".29 Treatment is up to 6 sessions, at least a month apart.29 In the first main trial, 70% improved by at least one grade on both doctor and patient ratings. With a dummy injection, 19% did.29

Side effects at the injection site were near-universal: 96% on Kybella against 81% on dummy injections.29 Swelling hit 87% (against 43%) and numbness 66% (against 6%).29 About 4 in 100 had nerve injury that caused an uneven smile. It went away in every case, after 44 days at the middle (median).29

The US regulator (FDA) warns about unapproved fat-dissolving products sold as Aqualyx, Lipodissolve, Lipo Lab and Kabelline.28 It has reports of permanent scars, serious infections, skin deformities, cysts and deep, painful knots.28

India note. A 2019 Indian study said Kybella and its Canadian twin weren't available in India. So the authors tested a generic deoxycholic acid under the chin in 50 people.30 Most needed 3 sessions, and the abstract describes no comparison group.30 We found no CDSCO approval for any fat-dissolving injection.

Do MIC, vitamin B12 or HCG shots help you lose weight?

We found no good evidence that MIC, B12 or HCG shots help weight loss, and the US approves no HCG product for it.31, 32, 34

Vitamin B12. Mayo Clinic says there's no solid proof that B12 shots help you lose weight.31 Doctors prescribe them for B12 deficiency and a type of anaemia (pernicious anaemia).31

MIC or lipotropic shots. They are not FDA-approved for weight loss, and most claims for them rest on personal stories.34 We found no controlled trial testing MIC shots for weight loss.

HCG. The FDA says HCG "has not been demonstrated to be effective therapy in the treatment of obesity".32 HCG plans come with a very low-calorie diet. The FDA says that diet raises the risk of gallstones, salt imbalances (electrolyte imbalance) and an irregular heartbeat.32 These are US statements; we found no Indian approval of HCG for weight.

Is there an approved weight-loss tablet in India?

Orlistat, a capsule, is the older weight-loss medicine available in India, and no semaglutide tablet is formally approved here for weight.24

Orlistat blocks an enzyme that digests fat (a lipase), so some fat passes out of the body.25 Its side effects include fatty stools, oily spotting and low levels of some vitamins.25 Our orlistat vs GLP‑1 post compares the two.

What about Saxenda? Saxenda is liraglutide at 3 mg a day. Its US label covers weight reduction (US label, not an Indian one).37 We found no Saxenda approval or launch in India. Eris's liraglutide pen, backed for weight by CDSCO's panel in February 2025, is the closest case.35 We found no report of its final approval or launch.

The other liraglutide brands we found, Victoza, Lirafit and Biocon's, were launched or approved for type 2 diabetes.20, 21, 36 CDSCO's panel noted that Biocon's UK approval covered weight, but Biocon asked for diabetes in India.22 Still, the 2026 AIIMS Bhopal review lists liraglutide among the obesity medicines available in India.24

Food and activity changes, older pills, GLP‑1 medicines and surgery are compared side by side in Guide 3: Your options.

Questions people ask

Is Ozempic approved for weight loss in India?

No. Ozempic is approved in India for type 2 diabetes. Wegovy and its second brand Poviztra, and some generic semaglutides, are approved for weight management.17, 7, 14, 15

Is Mounjaro approved for weight loss in India?

Sources disagree. Lilly launched Mounjaro in March 2025, after CDSCO authorisation, as a treatment for obesity, overweight and type 2 diabetes. A 2026 AIIMS Bhopal review says it is approved for diabetes and used for obesity. We found no published date for a formal weight approval.10, 24

Is Saxenda available in India?

We found no Saxenda approval or launch in India. A CDSCO panel recommended Eris's liraglutide pen for weight management in February 2025. We found no report of its final approval or launch. The other liraglutide brands we found are for type 2 diabetes.20, 21, 35

Are fat-dissolving injections safe?

In the US, only Kybella is approved, and only for fat under the chin. The FDA has reports of scars, serious infections and skin deformities from unapproved products.28, 29

Can you get a weight-loss injection without a prescription in India?

No. GLP-1 medicines can't be bought over the counter. A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.39

How we researched this

We read 7 sets of CDSCO expert-panel minutes (April 2023 to March 2026) and CDSCO's 2024 new-drug list. We added company press releases and named news reports, all opened on 5 October 2026.

Where we found no formal approval date, the table gives the panel recommendation or the launch date, and says which. Some sources are American: the Kybella and Wegovy labels, and the warnings on fat-dissolving shots and HCG. We found no Indian equivalent.

On 5 October 2026 we checked the top 3 search results for "weight loss injection india". All 3 were clinic pages. None named a CDSCO approval. One described the injections it listed, including lipotropic and HCG shots, as "medically approved treatments".

We found no CDSCO approval date for Ozempic or Poviztra, so we show launch or announcement dates. Victoza's 2010 dates come from Novo Nordisk's launch press release. Where sources disagree, as on Mounjaro's weight approval, we say so. We found no controlled trial of MIC shots for weight loss. We left prices off this page; Guide 6 lists MRPs.

Before you move on

  • Semaglutide 2.4 mg and tirzepatide are the GLP‑1 injections sold in India for weight. A CDSCO panel also backed a liraglutide pen in 2025.
  • Ozempic, Rybelsus, Victoza and Trulicity were launched or approved for type 2 diabetes, not weight.
  • Generic semaglutides are approved brand by brand; some cover weight, some only diabetes.
  • Fat-dissolving, MIC and HCG shots are not approved weight-loss treatments.
  • All GLP‑1 medicines need a prescription from a doctor.
Guide 6: Seeing a doctor, and the medicinesI'm considering it for my weightCould it be an option?

More from the India blog

INIndiaMedicinesWegovy vs Ozempic: same medicine, different brand? INIndiaMedicinesLiraglutide, Saxenda and Victoza: the older GLP-1 in India
INIndiaComing soonOrlistat vs GLP-1 medicines: how do they compare?
About GLP Guidebook

The monthly India update

An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: new brands, price changes, approvals and recalls. How we write

Was this post easy to understand?

Sources

  1. Central Drugs Standard Control Organisation (CDSCO). Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), meeting of 13 August 2024: records that semaglutide pens 0.25–2.4 mg were approved on 20.04.2022, semaglutide tablets on 27.07.2020, and tirzepatide pens (type 2 diabetes) on 19.01.2024. PDF · archived copy
  2. Medical Dialogues. Semaglutide prescription to be restricted to endocrinologists only: CDSCO panel tells Novo Nordisk (78th SEC meeting, 24–25 August 2021; treatment "up to 68 weeks"). 11 September 2021. Link
  3. Deccan Herald (PTI). Novo Nordisk launches anti-obesity drug Wegovy in India (once-weekly pen, 0.25 to 2.4 mg). 24 June 2025. Link
  4. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), meeting of 23 March 2026, item 3: Wegovy for adolescents 12 and over with obesity and body weight above 60 kg, "prescribed by registered Endocrinologist or pediatrician". PDF · archived copy
  5. IndiaMedToday. Novo Nordisk's Wegovy gets CDSCO nod for adolescent obesity in India. 29 May 2026. Link
  6. Business Standard. Novo Nordisk's Wegovy gets CDSCO nod for fatty liver disease indication. 17 July 2026. Link
  7. India Infoline. Novo Nordisk expands obesity-care reach in India with Emcure Pharma collaboration (Poviztra, "a second brand of Wegovy"). 10 November 2025. Link
  8. CDSCO. List of new drugs approved in the year 2024 (to 26.11.2024), row 1: tirzepatide pen for type 2 diabetes, issued 19 January 2024. PDF · archived copy
  9. ThePrint. Blockbuster diabetes & obesity drug gets nod for India launch (quotes the June 2024 SEC recommendation "for chronic weight management"). 2 July 2024. Link
  10. Business Standard. Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India (single-dose vial, after CDSCO marketing authorisation). 20 March 2025. Link
  11. Business Standard. Mounjaro KwikPen by Lilly debuts in India for diabetes, obesity (cleared in June 2025; multi-dose pen). 13 August 2025. Link
  12. Cipla. Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes ("the second brand of Lilly's tirzepatide in India"). Press release, 10 December 2025. PDF
  13. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), meeting of 9 December 2025, items 4–7: semaglutide for chronic weight management (Sun Pharma, Alkem, Zydus) and for type 2 diabetes (Zydus), after Phase III trial reports. PDF · archived copy
  14. Sun Pharmaceutical Industries. Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management (Noveltreat). Press release, 23 January 2026. PDF
  15. Alkem Laboratories. Alkem launches semaglutide injection in India (Semasize, Obesema, Hepaglide; DCGI approval for type 2 diabetes and chronic weight management). Press release, 21 March 2026. PDF
  16. Pearce IP. Generic semaglutide launches in India, including by Dr Reddy's, Zydus, Alkem, Sun Pharma and Glenmark. 21 March 2026. Link
  17. Business Standard. As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices ("Ozempic is indicated for diabetes management, while Wegovy is prescribed for obesity and weight management"; "at least 17 generic versions"). 31 March 2026. Link
  18. Business Standard. Novo Nordisk launches Ozempic in India (type 2 diabetes; 0.25, 0.5 and 1 mg). 12 December 2025. Link
  19. Medical Dialogues. Novo Nordisk gets CDSCO panel nod for Rybelsus label update (Rybelsus "indicated for the treatment of type 2 diabetes mellitus"). 10 September 2025. Link
  20. Business Standard. Glenmark cuts diabetes drug cost by 70% with first Indian biosimilar launch (Lirafit, DCGI-approved, type 2 diabetes; Victoza daily doses). 3 January 2024. Link
  21. Pearce IP. Approval alert: Biocon's generic liraglutide approved in India (type 2 diabetes). 2 June 2025. Link
  22. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), meeting of 11 July 2024, item 4 (Biocon liraglutide: UK approval for weight management; type 2 diabetes proposed in India). PDF · archived copy
  23. BioSpectrum. Once-a-week drug for type 2 diabetes launched by Lilly India (Trulicity). 3 March 2016. Link
  24. Atal S, Agrawal C, Gupta R, Sadasivam B (AIIMS Bhopal). Pharmacological management of obesity: current landscape and emerging therapies. Indian J Pharmacol, September 2026. DOI · Full text
  25. Madhu SV, Kapoor N, Das S, Raizada N, Kalra S. ESI clinical practice guidelines for the evaluation and management of obesity in India: an update (2025). Indian J Endocrinol Metab, 2025. Recommendation B.1 and Table 1 (side effects, warnings, contraindications). DOI · Full text
  26. Outlook India (PTI). Inspections, surveillance to continue against unauthorised sale, promotion of GLP-1 weight-loss drugs: Govt. 1 April 2026. Link
  27. Medical Dialogues. No ads for prescription drugs: panel flags surrogate advertising, misleading promotions of GLP-1 obesity drugs (CDSCO advisory of 10 March 2026). 18 April 2026. Link
  28. US Food and Drug Administration (US, not Indian). Using fat-dissolving injections that are not FDA approved can be harmful. Content current as of 20 December 2023. FDA
  29. Kythera Biopharmaceuticals. Kybella (deoxycholic acid) injection, US prescribing information, 2015 (US label, not an Indian one): sections 1, 2.1, 5.1, 6.1 (Table 1) and 14 (Table 2). PDF
  30. Shome D, Khare S, Kapoor R. The use of deoxycholic acid for the clinical reduction of excess submental fat in Indian patients. J Drugs Dermatol 2019;18(3):266–272. PMID 30909331
  31. Mayo Clinic. Vitamin B-12 injections for weight loss: do they work? Expert answer. Mayo Clinic
  32. US Food and Drug Administration (US, not Indian). Questions and answers on HCG products for weight loss. Content current as of 4 May 2016. FDA
  33. Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026 (US label, not the Indian one): section 5.2, acute pancreatitis. PDF
  34. Medical News Today. Lipotropic injections: cost, dosage and risks. Medically reviewed by Jillian Foglesong Stabile MD; updated 26 January 2026. Link
  35. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), meeting of 6 February 2025, item 8: Eris Lifesciences' synthetic liraglutide 6 mg/ml pre-filled pen "indicated for the treatment of weight management", recommended with a Phase III waiver and a Phase IV condition. PDF · archived copy
  36. Business Standard (press release). One drug, four benefits: Novo Nordisk launches Victoza in India (DCGI approval Jan 2010, type 2 diabetes in adults). 7 June 2010. Link
  37. Novo Nordisk. Saxenda (liraglutide) US prescribing information, revised February 2026 (US label, not an Indian one): section 1 and 2.2 ("3 mg daily"). PDF
  38. Medical Dialogues. Recalls by Dr Reddy's, Torrent put spotlight on quality standards in India's semaglutide market (Obeda, Semalix and Usema batches). 10 July 2026. Link
  39. Press Information Bureau (PIB) Research. GLP-1 drugs: use, risks, and regulation. Government backgrounder, 1 April 2026. PDF
  40. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 100th meeting, 20–21 April 2023, item 1 (tirzepatide): "sold by retail under prescription of Endocrinologist or internal medicine specialists only". PDF · archived copy
  41. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), meeting of 13–14 February 2024, item 3 (semaglutide): approved warning "To be sold by retail on the prescription of an Endocrinologist, and Internal medicine". PDF · archived copy
  42. Misra A et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009;57:163–70. PMID 19582986

Last checked 5 Oct 2026 · Next review due 5 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write